Study Stopped
due to poor patient recruitment
Evaluation of Compliance With Management of Acute Coronary Syndrome on Discharge From Cardiac Intensive Care
SCAVANCE
1 other identifier
observational
1,000
1 country
49
Brief Summary
To study compliance with secondary prevention during the first months following discharge from the cardiac intensive care unit (CIC) of patients experiencing a first episode of acute coronary syndrome : quantitative compliance over 3 months with the two principal treatments of the prescription (a statin - rosuvastatin, Crestor® and a platelet aggregation inhibitor - clopidogrel, Plavix®), using an electronic measure system ("intelligent blister" pack®);
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2010
Shorter than P25 for all trials
49 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 25, 2010
CompletedStudy Start
First participant enrolled
April 1, 2010
CompletedFirst Posted
Study publicly available on registry
April 16, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2011
CompletedOctober 4, 2010
October 1, 2010
11 months
March 25, 2010
October 1, 2010
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
To measure, using an electronic system ("intelligent blister pack®"), the duration of treatment and number of treatment intake per day over 3 months with statin and oral antiplatelet therapy following an inaugural acute coronary syndrome.
3 months / every day
Secondary Outcomes (3)
Analysis of the duration of treatment and number of treatment intake per day at 1 month and 2 months with a statin and a platelet aggregation inhibitor, using an electronic system ("intelligent blister pack®").
1 and 2 months / every day
Describe global compliance with the entire prescription over 6 months
6 months / Once at 6 months follow-up
Determine the factors influencing compliance with treatment on discharge from CIC (discharge treatment including a statin - rosuvastatin, Crestor® and a platelet aggregation inhibitor - clopidogrel, Plavix®).
6 months
Eligibility Criteria
First 10 patients admitted to the CIC unit for a first episode of acute coronary syndrome, in whom the CIC cardiologist considers that Crestor® - rosuvastatin is the most appropriate statin for management in hospital, in combination with a platelet aggregation inhibitor (Plavix® - clopidogrel).
You may qualify if:
- Patient admitted to the CIC unit for a first episode of acute coronary syndrome, in whom the CIC cardiologist considers that Crestor® -rosuvastatin is the most appropriate statin, in combination with a platelet aggregation inhibitor (Plavix®-clopidogrel)
- Patient giving his/her oral consent to participate in the study.
- Patient not previously treated by a lipid-lowering drug.
You may not qualify if:
- Patient with a known history of coronary heart disease.
- Patient whose treatment on discharge comprises only one of the two study treatments
- Patient participating or who has participated in the previous 3 months in a biomedical research study in cardiology.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (49)
Research Site
Antony, France
Research Site
Argenteuil, France
Research Site
Arras, France
Research Site
Avignon, France
Research Site
Bayonne, France
Research Site
Boulogne-Billancourt, France
Research Site
Bourges, France
Research Site
Caen, France
Research Site
Cholet, France
Research Site
Clamart, France
Research Site
Colmar, France
Research Site
Creil, France
Research Site
Dijon, France
Research Site
Eaubonne, France
Research Site
Épernay, France
Research Site
La Rochelle, France
Research Site
La Tronche, France
Research Site
Le Chesnay, France
Research Site
Le Coudray, France
Research Site
Le Plessis-Robinson, France
Research Site
Lens, France
Research Site
Libourne, France
Research Site
Lomme, France
Research Site
Lorient, France
Research Site
Lyon, France
Research Site
Mantes-la-Jolie, France
Research Site
Marseille, France
Research Site
Metz, France
Research Site
Montfermeil, France
Research Site
Neuilly-sur-Seine, France
Research Site
Nevers, France
Research Site
Niort, France
Research Site
Orléans, France
Research Site
Paris, France
Research Site
Pau, France
Research Site
Perpignan, France
Research Site
Pessac, France
Research Site
Périgueux, France
Research Site
Reims, France
Research Site
Rodez, France
Research Site
Saint-Nazaire, France
Research Site
Salouël, France
Research Site
Schiltigheim, France
Research Site
Strasbourg, France
Research Site
Toulouse, France
Research Site
Troyes, France
Research Site
Valence, France
Research Site
Vandœuvre-lès-Nancy, France
Research Site
Villeneuve-Saint-Georges, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Pascal Piedbois
AstraZeneca
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
March 25, 2010
First Posted
April 16, 2010
Study Start
April 1, 2010
Primary Completion
March 1, 2011
Study Completion
March 1, 2011
Last Updated
October 4, 2010
Record last verified: 2010-10